Journal of Clinical Oncology
Articles in this Issue
Anti-CD38 treatment patterns in multiple myeloma patients with Medicare/Medicaid versus private insurance.
e19575 Background: Multiple myeloma (MM) is one of the most common hematological malignancies, and the incidence of MM con...
Long-term outcomes of laparoscopic versus open gastrectomy for far-advanced gastric cancer after preoperative chemotherapy.
e16072 Background: Evidence supporting the implementation of laparoscopic gastrectomy (LG) for far-advanced gastric cancer...
Prognostic value of serum tumor markers in phase I immunotherapy trials: A single-institution retrospective analysis.
e14534 Background: Serum tumor markers are routinely monitored in patients with advanced solid tumors, but their utility i...
BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
12080 Background: Chemotherapy-induced peripheral neuropathy (CIPN) and Neutropenia are significant side effects associate...
The efficacy and safety of calmangafodipir in preventing chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
e24208 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-limiting toxicity of oxaliplatin-...
Treatment patterns and survival outcomes in colon cancer patients with autism spectrum disorder: A propensity score–matched retrospective multicenter cohort study.
e15729 Background: Patients with autism spectrum disorder (ASD) face documented barriers to cancer care, yet oncologic out...
A first-in-human (FiH) phase I study of GFS202A, a GDF15/IL-6 bispecific antibody, in advanced cancer patients (pts) with pre-cachexia or cachexia.
12055 Background: Cachexia is a common syndrome in cancer pts, associated with weight loss, impaired quality of life, and...
Weekend admission and inpatient outcomes in hospitalized patients with acute promyelocytic leukemia.
e18546 Background: Acute promyelocytic leukemia [APL] has historically been associated with significant early mortality, b...
PROGRESS: Implementation of a novel hybrid decentralized clinical trial to support precision oncology uptake at academic and community oncology practices in North Carolina.
e23150 Background: Rates of comprehensive molecular profiling (CMP), use of evidence-based genome-informed therapy (GIT),...
Fitness classification and induction intensity selection in AML practice: A contemporary real-world cohort study.
e18552 Background: Standard acute myeloid leukemia (AML) induction has historically relied on intensive cytarabine/anthrac...
Cancer patients' comfort with artificial intelligence in oncology care and first-round "AI chemo-teach" quality improvement initiatives.
e13652 Background: Artificial intelligence (AI)-powered tools are rapidly advancing oncology care, but patients’ acceptanc...
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.
7024 Background: Liso-cel is an autologous, CD19-directed CAR T cell product with established efficacy and safety across B...
A radiomics-based model for the prediction of WHO/ISUP in clear cell renal cell carcinoma using contrast-enhanced CT indicating response to TKI therapy.
e16522 Background: WHO/ISUP grade is a significant risk factor for the prognosis of patients with clear cell renal cell ca...
Phlebotomy, adherence, and hematocrit control in patients with polycythemia vera in the United States: Real-world analysis.
6568 Background: Polycythemia Vera (PV) is characterized by erythrocytosis. A key treatment goal in PV, for which phleboto...
Clinical utility of NGS in patient stratification for first-line chemotherapy in locally advanced/advanced GBC: A pilot study demonstrating the hypothesis.
e16244 Background: Gallbladder cancer is highly prevalent in Asian countries and is associated with poor survival outcomes...
Erythropoietin receptor (EPOR) expression to identify a biologically aggressive tumor phenotype in clear cell renal cell carcinoma.
e16521 Background: Clear cell renal cell carcinoma (ccRCC) demonstrates substantial biologic heterogeneity and variable cl...
Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy in early-stage triple-negative breast cancer: A systematic review and meta-analysis.
e12639 Background: Neoadjuvant immune checkpoint inhibition targeting the PD-1/PD-L1 pathway has become an integral compon...
Influence of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor–positive early breast cancer: A pooled meta-analysis of phase III clinical trials.
e12506 Background: Adjuvant cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve outcomes in hormone receptor–positive...
From multi-omics to clinical practice: BC-BioMIXER to predict PCR and guide individualized neoadjuvant chemotherapy for breast cancer.
e12551 Background: Early and accurate prediction of pathological complete response (pCR) is crucial for personalizing neoa...
A novel prognostic index for survival prediction in ovarian cancer: Beyond FIGO staging.
5577 Background: Prognostication in ovarian cancer is traditionally based on FIGO stage, although survival is influenced b...
Decoding spatial tumor heterogeneity via multi-view radiomics for long-term survival prediction in advanced NSCLC immunotherapy.
e20643 Background: Current radiomics models for NSCLC immunotherapy primarily focus on short-term outcomes (e.g., 6–12 mon...
Real-world survival benefit of glucagon-like peptide-1 receptor agonists (GLP-1 Ras) concomitant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy in hormone receptor-positive (HR+)/HER2− metastatic breast cancer: A large propensity-matched analysis.
1070 Background: Obesity increases hormone receptor-positive (HR+) breast cancer risk through adipose-derived estrogens an...
Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with <i>ERBB2</i> alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2644 Background: TAPUR is a phase II basket study evaluating the antitumor activity of commercially available targeted age...
Exosome whisperers: Decoding SPHK1's role in cisplatin-induced immune escape of NSCLC.
e20622 Background: Cisplatin, a key NSCLC chemotherapy, exhibits both cytotoxic and immunomodulatory effects. It influence...
Multi-modal AI modeling to predict clinical trial outcomes and benchmarks pan-RAS versus KRAS G12D inhibition in KRAS G12D–mutant PDAC.
4020 Background: In pancreatic ductal adenocarcinoma (PDAC), uncertainty persists regarding the optimal positioning of pan...